Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 3,528 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: biospecimen Collection Clear all

Conditions: Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Ovarian Low Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma
Interventions: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Tuvusertib, X-Ray Imaging; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 14
States / cities: Augusta, Georgia • Chicago, Illinois • Iowa City, Iowa + 8 more

Conditions: Cervical Cancer
Interventions: Questionnaires, Biological Samples; Behavioral · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 285 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Herpes Genitalis
Interventions: Blood sampling, Anogenital lesion swab collection; Procedure
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 22
States / cities: Long Beach, California • Los Angeles, California • San Francisco, California + 16 more

Conditions: Interference With Routine Analytical Tests, Stability of in Vitro Diagnostic Reagents, Illicit Drug Use
Interventions: Device storage condition, Interferent application; Device
Lead sponsor: Intelligent Bio Solutions Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: Neuroblastoma, Osteosarcoma, Other Solid Tumor Cancers
Interventions: Humanized 3F8 Bispecific Antibody, Blood draw; Biological · Other
Lead sponsor: Y-mAbs Therapeutics; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Hematopoietic and Lymphatic System Neoplasm
Interventions: Kate Farms 1.0, Standard of Care Nutritional Support, Survey Administration, Dietary Supplement, Biospecimen Collection, Electronic Health Record Review, Fiber and Dietary Assessments; Dietary Supplement · Other · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Alzheimer Disease
Interventions: 11C-ER176, 18F-florbetaben; Drug
Lead sponsor: Columbia University; Other
Eligibility: 50 Years and older
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Severe Combined Immunodeficiency, Malignancy, Hematologic, Neuroblastoma, Neoplasm, Mucopolysaccharidosis I
Interventions: Venipuncture; Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Leukemia, Burkitt Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Lymphoblastic Lymphoma, Mast Cell Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
Interventions: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Fludarabine, Total-Body Irradiation; Biological · Procedure · Drug + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cryopyrin-Associated Periodic Syndromes, Amyloidosis
Interventions: 124I AT-01; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Gallium Ga 68-labeled PSMA-11, Monosodium Glutamate, Positron Emission Tomography; Procedure · Drug · Dietary Supplement
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Trisomy 13, Trisomy 18, Trisomy 21, Aneuploidy
Interventions: Blood Draw; Procedure
Lead sponsor: Natera, Inc.; Industry
Eligibility: Female only
Enrollment: 937 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2023
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 16 more

Conditions: Congenital Anomaly, Pediatric Cancer
Interventions: Whole Genome Sequencing, Questionnaire Administration, Biospecimen collection, Laboratory Biomarker Analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 0 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: ACS (Acute Coronary Syndrome)
Interventions: Abbott i-STAT point of care (POC) device; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Charlotte, North Carolina • High Point, North Carolina • Winston-Salem, North Carolina

Conditions: Leukemia
Interventions: DNA analysis, Southern blotting, cytogenetic analysis, polymerase chain reaction; Genetic
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 161
States / cities: San Diego, California • San Francisco, California • Lewes, Delaware + 89 more

Conditions: Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions: Acolbifene Hydrochloride, Biospecimen Collection, Mammography, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 35 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Duarte, California • Chicago, Illinois • Kansas City, Kansas + 1 more

Conditions: Lung Cancer
Interventions: EBUS-TBNA; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Venipuncture, Lumbar Puncture; Diagnostic Test
Lead sponsor: Holy Cross Hospital, Florida; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma, Stage II Ovarian Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8
Interventions: Biospecimen Collection, Placebo Administration, Probiotic, Questionnaire Administration; Procedure · Drug · Dietary Supplement + 1 more
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Sepsis
Interventions: Suspected Sepsis Group - Diagnostic Measurements, Control Group - Diagnostic Measurements; Diagnostic Test
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma, Childhood Diffuse Midline Glioma, Childhood Glioblastoma, Childhood Malignant Glioma
Interventions: ATM Kinase Inhibitor AZD1390, Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, Survey Administration; Drug · Procedure · Radiation + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 12 Months to 22 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more

Conditions: Multiple Sclerosis, Myasthenia Gravis, Transverse Myelitis
Interventions: Blood Draw, Cheek swab; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2031
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Biospecimen Collection, Computed Tomography, Lenalidomide, Mosunetuzumab, Polatuzumab Vedotin, Positron Emission Tomography; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Duarte, California • Sacramento, California • Tampa, Florida + 5 more

Conditions: Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Hereditary Sideroblastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Shwachman-Diamond Syndrome, Hematologic Neoplasm With Germline GATA2 Mutation, Hematologic Neoplasm With Germline SAMD9 Mutation, Hematologic Neoplasm With Germline SAMD9L Mutation
Interventions: Treosulfan, Fludarabine Phosphate, Tacrolimus, Methotrexate, Lapine T-Lymphocyte Immune Globulin, Peripheral Blood Stem Cell Transplantation, Allogeneic Bone Marrow Transplantation, Quality-of-Life Assessment, Echocardiography, Multigated Acquisition Scan, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, X-Ray Imaging, Computed Tomography; Drug · Biological · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 1 Year to 49 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 24
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 20 more

Search by objective public record fields.

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Community Awareness, Resources and Education (CARE II) Project: Project 1

An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe.

Interference and Stability Evaluation of the Intelligent Fingerprinting Drug Screening System

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Sustained Oral Fiber Supplementation for Patients Undergoing Treatment for Hematological Malignancies

Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease

Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products

Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome

Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load

Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer

Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial

Genetic Overlap Between Anomalies and Cancer in Kids in the Children's Oncology Group: The COG GOBACK Study

Assessing Chest Pain Using Point-of-Care High-Sensitivity Troponin I in the Emergency Department

Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Utility of Endobronchial Ultrasound Guided Needle Biopsy in Early Stage Non- Small Cell Lung Cancer (NSCLC)

A Longitudinal Analysis of Biomarkers in Patients With ALS

Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy

Mitochondrial Dysfunction Contributes to Sepsis Induced Cardiac Dysfunction

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Serum Auto-Antibodies in Neurological Diseases

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)